Abbott Laboratories Corporation

Tap Holdings, LLC

Tap Pharmaceuticals, Inc.

Other

Tap Holding Inc.

Fortuna Haviv

Jonathan Greer

Michael F Bradley

Rolf E Swenson

Nicholas A Mort

Daryl Richard Sauer

Jack Henkin

Timothy D Fitzpatrick

Charles J Nichols

Milan Bruncko

Christopher R Dalton

Douglas M Kalvin

Lisa Marie Frey

Michele A Kaminski

John T Randolph

Wesley J Dwight

Andrew J Schneider

Bradley W Crawford

James D Ratajczyk

Daryl R Sauer

Robert W Denet

Christopher Bieniarz

Francis A Kerdesky

Yi Shi

George W Carter

Roland L Walters

Mazhar Husain

John A DeMattei

Bryan K Erickson

Luk Chiu Li

Mark Bures

Dominique Bridon

William A Boulanger

Francis E Fischer

Fanfeng Ma

Friedrich W Richter

Jingfeng Song

Philip Waid

Siriporn Toongsuwan

Christopher A Palabrica

Compounds having the formula are angiogenesis inhibitors. Also disclosed are compositions containing the compounds, methods of making the compounds, and methods of treatment using the compounds.

Ureas having antiangiogenic activity

Parenteral formulations of peptides which are useful for sustained release are disclosed. Also disclosed are methods of preparation for the formulations.

Pharmaceutical formulation comprising a peptide angiogenesis inhibitor

Compounds of formula (SEQ ID NO:2) and (SEQ ID NO:3), which are useful for treating conditions that arise from or are exacerbated by angiogenesis, are described. Also disclosed are pharmaceutical compositions comprising these compounds, methods of treatment using these compounds, and methods of inhibiting angiogenesis.

Tetra-, penta-, hexa-  and heptapeptides having antiangiogenic activity

Compounds of formula (SEQ ID NO:1), which are useful for treating conditions that arise from or are exacerbated by angiogenesis, are described. Also disclosed are pharmaceutical compositions comprising these compounds, methods of treatment using these compounds, and methods of inhibiting angiogenesis.

Hexa-, hepta-, and octapeptides having antiangiogenic activity

Hepta-, Octa-and nonapeptides having antiangiogenic activity

TRI-, TETRA-, and penta-peptides having antiangiogenic activity

Compounds having the formula (SEQ ID NO:1), which are useful for treating conditions that arise from or are exacerbated by angiogenesis, are described. Also disclosed are pharmaceutical compositions comprising these compounds, methods of treatment using these compounds, and methods of inhibiting angiogenesis.

Di-, tri-, and tetra-peptides having antiangiogenic activity

N-alkylated peptides having antiangiogenic activity

Peptide antiangiogenic drugs

Peptides having antiangiogenic activity

Disclosed are 3&prime;,3&prime;-N-bis-desmethyl-3&prime;-N-cycloalkyl-6-O-methyl-11-deoxy-11,12-cyclic carbamate erythromycin A derivatives which are antagonists of lutenizing hormone-releasing hormone (LHRH). Also disclosed are pharmaceutical compositions comprising the compounds, to methods of using the compounds and to the process of making the same.

3&prime;,3&prime;-N-bis-desmethyl-3&prime;-N-cycloalkyl erythromycin derivatives as LHRH antagonists

The present invention relates to a class of pentapeptide analogs of LHRH. These compounds are useful in the treatment of disease conditions which are mediated by reproductive hormones, including benign prostate hyperplasia, prostate tumors, breast and ovaries tumors, cryptorchidism, hirsuitism, gastric motility disorders, dysmenorrhea, and endometriosis.

Pentapeptide LHRH antagonists

The present invention relates to a class of heptapeptide analogs of LHRH. These compounds are useful in the treatment of disease conditions which are mediated by reproductive hormones, including benign prostate hyperplasia, prostate tumors, breast and ovaries tumors, cryptorchidism, hirsuitism, gastric motility disorders, dysmenorrhea, and endometriosis.

C-terminus modified heptapeptide LHRH analogs

Disclosed are 3'-N-desmethyl-3'-N-susbstituted-6-O-methyl-11-deoxy-11,12-cyclic carbamate erythrolide A derivatives which are antagonists of luteinizing hormone-releasing hormone (LHRH). Also disclosed are pharmaceutical compositions comprising the compounds, to methods of using the compounds and to the process of making the same.

Macrolide LHRH antagonists

Growing community of inventors

Deerfield, IL, United States of America

Fortuna Haviv